0001567619-20-013325.txt : 20200715
0001567619-20-013325.hdr.sgml : 20200715
20200715213223
ACCESSION NUMBER: 0001567619-20-013325
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200430
FILED AS OF DATE: 20200715
DATE AS OF CHANGE: 20200715
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: FUCHS HENRY J
CENTRAL INDEX KEY: 0001197355
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-26727
FILM NUMBER: 201030578
MAIL ADDRESS:
STREET 1: C/O BIOMARIN PHARMACEUTICAL INC.
STREET 2: 105 DIGITAL DRIVE
CITY: NOVATO
STATE: CA
ZIP: 94949
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: BIOMARIN PHARMACEUTICAL INC
CENTRAL INDEX KEY: 0001048477
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 680397820
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 105 DIGITAL DRIVE
CITY: NOVATO
STATE: CA
ZIP: 94949
BUSINESS PHONE: 4155066700
MAIL ADDRESS:
STREET 1: 105 DIGITAL DRIVE
CITY: NOVATO
STATE: CA
ZIP: 94949
4
1
doc1.xml
FORM 4
X0306
4
2020-04-30
0
0001048477
BIOMARIN PHARMACEUTICAL INC
BMRN
0001197355
FUCHS HENRY J
C/O BIOMARIN PHARMACEUTICAL INC.
770 LINDARO ST.
SAN RAFAEL
CA
94901
0
1
0
0
President, Worldwide R&D
Common Stock
2020-04-30
5
A
0
339
62.586
A
102995
D
Common Stock
2020-07-13
4
M
0
224
67.81
A
103219
D
Common Stock
2020-07-13
4
M
0
13810
67.81
A
117029
D
Common Stock
2020-07-13
4
M
0
8977
63.10
A
126006
D
Common Stock
2020-07-13
4
S
0
23011
130.00
D
102995
D
Stock Option (Right to buy Common Stock)
67.810
2020-07-13
4
M
0
224
0
D
2017-01-15
2023-05-14
Common Stock
224
1250
D
Stock Option (Right to buy Common Stock)
67.81
2020-07-13
4
M
0
13810
0
D
2013-11-15
2023-05-14
Common Stock
13810
75716
D
Stock Option (Right to buy Common Stock)
63.10
2020-07-13
4
M
0
8977
0
D
2014-12-04
2024-06-03
Common Stock
8977
49423
D
Represents shares acquired by the reporting person on April 30, 2020, pursuant to the issuer's Employee Stock Purchase Plan.
Trade made pursuant to a 10b5-1 plan executed on March 11, 2020.
The price in column 4 is the weighted average price. The price actually received ranged from $130.00 to $130.025. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.
Reflects the number of options outstanding after the transactions from this specific stock option grant.
/s/ Eric Fleekop, Attorney-in-Fact
2020-07-15